NCT05533411View on ClinicalTrials.gov

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions
Healthy
Interventions
DRUG

Donanemab

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (2)

100034

Peking University First Hospital, Beijing

410013

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY